
==== Front
ACS OmegaACS OmegaaoacsodfACS Omega2470-1343American Chemical Society 3145951610.1021/acsomega.8b03284ArticleThree-Component Cascade Reaction of 1,1-Enediamines, N,N-Dimethylformamide Dimethyl Acetal,
and 1,3-Dicarbonyl Compounds: Selective Synthesis of Diverse 2-Aminopyridine
Derivatives Zi Quan-Xing Yan Sheng-Jiao *Yang Chang-Long Li Kun Lin Jun *Key Laboratory of Medicinal Chemistry
for Natural Resource, Ministry of Education, School of Chemical Science
and Technology, Yunnan University, Kunming 650091, P. R. China* E-mail: yansj@ynu.edu.cn. Phone/Fax: +86 87165031633 (S.-J.Y.).* E-mail: linjun@ynu.edu.cn Phone/Fax: +86 87165031633 (J. L.).07 02 2019 28 02 2019 4 2 2863 2873 25 11 2018 25 01 2019 Copyright © 2019 American Chemical Society2019American Chemical SocietyThis is an open access article published under an ACS AuthorChoice License, which permits copying and redistribution of the article or any adaptations for non-commercial purposes.

A novel approach
has been developed for the synthesis of three
kinds of highly functionalized 2-aminopyridine derivatives (APDs)
through a three-component reaction of 1,1-enediamines (EDAMs) 1, N,N-dimethylformamide
dimethyl acetal (DMF-DMA) 2, and 1,3-dicarbonyl compounds 3–5 via a base-promoted cascade reaction,
producing the desired products in good to excellent yields. This method
represents a route to obtain a novel class of APDs in a concise, rapid,
and practical manner. This approach is particularly attractive because
of the following features: low cost, mild temperature, atom economy,
high yields, and potential biological activity of the product.

document-id-old-9ao8b03284document-id-new-14ao-2018-03284zccc-price
==== Body
Introduction
The 2-aminopyridine
derivatives (APDs) are one of the most important
classes of N-containing heterocycles, which are also ubiquitous structural
motifs in natural or synthetic biologically active molecules or drugs.
This kind of compounds usually have broad spectrum biological activity,
including anti-HIV,1 antitumor2−9 (Figure 1; Crizotinib2,3 and Asciminib4), anti-inflammatory,10 antifungal,11 antihistamine,12,13 antidepressant, antiarthritic, santidiabetic, antiglaucoma,14 and antiprion (Figure 1).15 These derivatives
are widely used as inhibitors of a variety of proteins, such as activin
A receptor type 1 (ACVR1),16 nitric oxide
synthase 1 (NOS1),17,18 A2A adenosine receptor
(ADORA2A) (Figure 1),19 and so forth.20 Consequently, various methods for the synthesis of 2-aminopyridines
have been developed.21−27 The classic methods include the nucleophilic substitution reaction
(SN) of 2-bromopyridines (Scheme 1a),21,22 ruthenium-catalyzed cyclization
reaction (Scheme 1b),23 nucleophilic reagents reaction with in situ
generated 1,4-oxazepines from N-propargylic β-enaminones followed
by spontaneous N-deformylation to APDs (Scheme 1c),24,25 and ruthenium-mediated
[2 + 2 + 2] cycloaddition of α,ω-diynes and cyanamides
(Scheme 1d).26 Although these methods have been very valuable
in the synthesis of APDs, they generally have some shortcomings, including
the complexity of the structure of the substrates for the synthesis
of APDs requires multistep and hazardous processes for its construction,
the approach often requires harsh conditions such as the use of a
metal-catalyst, and the yield and atom economy do not meet the demands
of medical and biological research.

Figure 1 Bioactive 2-aminopyridines, indenopyridines,
and the target compounds 6–8.

Scheme 1 Methods for the Synthesis of APDs
In addition, indanone derivatives
are considerably important because
of their interesting biological activities.28−30 Among them,
indenopyridine derivatives are an important class of pharmaceuticals
and bioactive natural products as a result of their significant and
wide-spectrum biological activities and are widely used as antitumor
or antiproliferative drugs,28,29 antimalarial agents,
and ADORA2A antagonist agents (Figure 1).19 Although there are
some methods for the synthesis of these molecules,28−32 these methods require multistep synthesis and strict
anhydrous conditions. Thus, there is a need for the development of
concise and effective methods for preparing the target compound library.

The 1,1-enediamines (EDAMs) are a variety of building blocks that
are usually used as bis-nucleophiles (α-carbon and N as nucleophilic
sites) to react with bis-electrophiles and produce heterocyclic compounds,
including pyridin-2-ones, pyrimidin-4-ones, imidazopyridinium derivatives,
and morphan derivatives.33−40 As part of our ongoing research effort, we used EDAMs as a substrate
to react with dimethylformamide dimethyl acetal (DMF-DMA) 2 and 1,3-dicarbonyl compounds 3 for the synthesis of
2-aminopyridines 6 (Scheme 1). Notably, the reaction for synthesis of
the target compounds 6 is completely different from the
reported reaction. In this study, the C(1) of EDAMs 1 serves to attack the electrophilic sites C(1) of 1,3-dicarbonyl
compounds 3 maybe as a result of the high eletrophilicity
of the C(1) of substrate 3 and the little steric effects
of the R′ group of compound 3. In addition, on
the basis of the splicing principle of the molecular structure of
the drug, we combined the two active core structures (cyclohexanone/indanone
and 2-aminopyridine) in the target compounds with the aim of producing
a new class of pharmaceutical molecule which may possess potential
biological activities. Accordingly, the cyclohexanone-fused APDs 7 and the indenopyridine derivatives 8 were easily
prepared by this method. Here, the N(2) of EDAMs 1 serves
to attack the electrophilic sites C(1) of 1,3-dicarbonyl compounds 4/5 maybe as a result of the low eletrophilicity of the C(1)
of substrate 4/5 and the steric effects of the R′
group of compound 4/5 (Scheme 1). Therefore, we can successfully regioselectively
synthesize three kinds of 2-aminopyridines based on the structural
difference of the substrates 3–5 (Scheme 1). This approach provides the
key information to design new substrates to react with EDAMs to synthesize
various 2-aminopyridines, 2-aminoquinolones, 2-aminopyrroles, 2-aminoindoles,
and so forth, via one-pot multicomponent reactions rather than multistep
synthesis.

Results and Discussion
To find the optimal reaction
conditions for the synthesis of our
target molecule, the reaction of (Z)-N-(4-methylphenethyl)-2-nitroethene-1,1-diamine 1b, DMF-DMA 2 and ethyl 3-oxobutanoate (3a) was chosen as
the model reaction. First, the three-component reaction was performed
in different solvents, which included acetone, ethanol, acetonitrile,
and 1,4-dioxane, at reflux conditions (Table 1, entries 1–4). The results showed
that the reaction could not proceed at all. Then, Cs2CO3 was added to the mixture as a promoter in the above-mentioned
solvents at the reflux temperature (Table 1, entries 5–8). The results revealed
that the reaction promoted by Cs2CO3 still could
not proceed in acetone, ethanol, or acetonitrile (Table 1, entries 5–7). Fortunately,
however, when 1,4-dioxane was used as the solvent under the same conditions,
the reaction produced the target compound with an excellent yield
(88%) (Table 1, entry
8). The use of another inorganic base, namely, K2CO3, as promoter with acetonitrile or 1,4-dioxane as solvent
and at reflux conditions, revealed that only when using 1,4-dioxane
the reactions proceed smoothly and can produce the target compound
in good yield (Table 1, entry 10). On the basis of these results, the stronger organic
base potassium tert-butoxide (t-BuOK) was separately
added to acetone, ethanol, acetonitrile or 1,4-dioxane at reflux conditions
for 12 h (Table 1,
entries 11–14). The results indicated that positive results
can only be obtained with 1,4-dioxane (Table 1, entry 14). On the basis of the above findings,
we concluded that 1,4-dioxane is the optimal solvent for this reaction.
We also compared yields obtained with the three promoters K2CO3, Cs2CO3, and t-BuOK and found that the best promoter is Cs2CO3 (Table 1, entry 8
vs 10 &14). Next, the reaction times were evaluated (Table 1, entry 8 vs 15).
We found that the best reaction time was about 5 h. Finally, we additionally
examined the effects of the amount of promoter on the reaction yields.
When the amount of catalyst Cs2CO3 was adjusted
to 10% (0.01 mmol) of the amount of substrate 1b, the
reaction produced the target compound 6a with a 90% yield
(Table 1, entry 16
vs 15). Accordingly, we assumed that 0.05 equiv Cs2CO3 was sufficient for this reaction.

Table 1 Optimization
of the Reaction Conditiona
entry	solvent	catalyst	T (°C)	t (h)	yieldb (%)	
1	acetone	 	reflux	12	n.r	
2	EtOH	 	reflux	12	n.r	
3	acetonitrile	 	reflux	12	n.r	
4	1,4-dioxane	 	reflux	12	n.r	
5	acetone	Cs2CO3c	reflux	12	n.r	
6	EtOH	Cs2CO3c	reflux	12	n.r	
7	acetonitrile	Cs2CO3c	reflux	12	n.r	
8	1,4-dioxane	Cs2CO3c	reflux	12	88	
9	acetonitrile	K2CO3c	reflux	12	n.r	
10	1,4-dioxane	K2CO3c	reflux	12	85	
11	acetone	t-BuOkc	reflux	12	n.r	
12	EtOH	t-BuOkc	reflux	12	n.r	
13	acetonitrile	t-BuOkc	reflux	12	n.r	
14	1,4-dioxane	t-BuOkc	reflux	12	86	
15	1,4-dioxane	Cs2CO3c	reflux	5	91	
16	1,4-dioxane	Cs2CO3d	reflux	5	90	
a Reaction conditions:
EDAM 1b (1.0 mmol), DMF-DMA 2 (1.5 mmol), 3a (1.0 mmol) and solvent (8 mL).

b Isolated yield based on 1b.

c Catalyst (0.05 mmol).

d Catalyst (0.1 mmol).

With the optimal conditions in hand,
we explored the scope and
limitations of the three-component cascade reaction with various EDAMs
and a variety of 1,3-dicarbonyl compounds. The results revealed that
in all cases the reaction proceeded smoothly in 1,4-dioxane at reflux
conditions for about 5 h (Table 2, entries 1–16). The different substituent groups
(R) of the EDAMs 1 usually had a slight effect on the
yields, but the difference is very small, and we cannot ascertain
the effect of any specific substituent. However, the substituent group
of 1,3-dicarbonyl compounds 3 has an obvious effect on
the yield of compounds 6. In general, the substrates 3a and 3b are usually more favorable to the yield
of the target compounds than the substrates 3c–3e. Overall, the different substituted substrates 1 and 3 easily reacted with DMF-DMA 2 to
produce compound 6 with good to excellent yields (74–92%).

Table 2 Synthesis of 2-Aminopyridines 6a
entry	R	R′	R″	1	3	6	yieldb (%)	
1	p-CH3C6H4CH2CH2	CH3	OCH2CH3	1b	3a	6a	91	
2	C6H5CH2CH2	CH3	OCH2CH3	1c	3a	6b	91	
3	m-FC6H4CH2CH2	CH3	OCH2CH3	1d	3a	6c	92	
4	p-ClC6H4CH2	CH3	OCH2CH3	1f	3a	6d	91	
5	p-FC6H4CH2	CH3	OCH2CH3	1g	3a	6e	91	
6	p-CH3OC6H4CH2CH2	CH3	CH3	1a	3b	6f	89	
7	p-CH3C6H4CH2CH2	CH3	CH3	1b	3b	6g	92	
8	C6H5CH2CH2	CH3	CH3	1c	3b	6h	91	
9	m-FC6H4CH2CH2	CH3	CH3	1d	3b	6i	92	
10	o-FC6H4CH2CH2	CH3	CH3	1e	3b	6j	91	
11	p-ClC6H4CH2	CH3	CH3	1f	3b	6k	90	
12	p-CH3C6H4CH2CH2	CF3	CF3	1b	3c	6l	87	
13	m-FC6H4CH2CH2	CF3	CF3	1e	3c	6m	85	
14	p-ClC6H4CH2	CF3	Ph	1f	3d	6n	84	
15	C6H5CH2CH2	Ph	Ph	1c	3e	6o	76	
16	m-FC6H4CH2CH2	Ph	Ph	1e	3e	6p	74	
a Reaction conditions: 1 (1.0 mmol), 2 (1.5
mmol), 3 (1.0 mmol),
and solvent (8 mL).

b Isolated
yield based on 1.

To further investigate the scope and limitations of the cascade
reaction, we reacted cyclic 1,3-dicarbonyl compounds (cyclohexane-1,3-dione
derivatives) with various EDAMs 1 and DMF-DMA 2, and we find that the optimal reaction time is about 10 h. Interestingly,
the reaction produced another kind of 2-aminopyridines 7 (Table 3, entries
1–14). In this reaction, the C(1) of EDAMs 1 serves
to attack the electrophilic sites C(1′) of the intermediate
formed from substrate 4 and DMF-DMA 2 (Schemes 1 and 2). Thus, different substituted EDAMs were also used as a substrate
and reacted with DMF-DMA and cyclohexane-1,3-dione derivatives 4a–4b, which all produced the target compounds 7 with excellent yields, except for compound 7h (Table 3, entries
1–14). The substituted groups on substrates 1 and 4 had almost no effect on the yield, which
indicated that various substrates can produce ideal results.

Scheme 2 Proposed
Mechanism for the Formation of 2-Aminopyridines 6
Table 3 Synthesis of APDs 7a
entry	R	R′	1	4	7	yieldb (%)	
1	p-CH3OC6H4CH2CH2	CH3	1a	4a	7a	90	
2	p-CH3C6H4CH2CH2	CH3	1b	4a	7b	92	
3	C6H5CH2CH2	CH3	1c	4a	7c	92	
4	m-FC6H4CH2CH2	CH3	1d	4a	7d	90	
5	o-FC6H4CH2CH2	CH3	1e	4a	7e	90	
6	p-ClC6H4CH2	CH3	1f	4a	7f	90	
7	p-FC6H4CH2	CH3	1g	4a	7g	91	
8	C6H5	CH3	1h	4a	7h	76	
9	p-CH3OC6H4CH2CH2	H	1a	4b	7i	90	
10	p-CH3C6H4CH2CH2	H	1b	4b	7j	92	
11	C6H5CH2CH2	H	1c	4b	7k	91	
12	m-FC6H4CH2CH2	H	1d	4b	7l	90	
13	o-FC6H4CH2CH2	H	1e	4b	7m	91	
14	p-ClC6H4CH2	H	1f	4b	7n	91	
a Reagents and conditions: 1 (1.0 mmol), 2 (1.5 mmol), 4 (1.0 mmol)
and solvent (8 mL).

b Isolated
yield based on 1.

On the basis of above results, we examined the scope and limitations
of the cascade reaction using the cyclic 1,3-dicarbonyl compound 1H-indene-1,3(2H)-dione (Table 4, entries 1–8). The results
showed that the different substituent groups of EDAMs 1 usually had a slight effect on the yields. As a result, we can obtain
the target compounds 8 with excellent yields (Table 4, entries 1–8).

Table 4 Synthesis of APDs
8a
entry	R	1	8	yieldb (%)	
1	p-CH3OC6H4CH2CH2	1a	8a	89	
2	p-CH3C6H4CH2CH2	1b	8b	93	
3	C6H5CH2CH2	1c	8c	91	
4	m-FC6H4CH2CH2	1d	8d	91	
5	o-FC6H4CH2CH2	1e	8e	92	
6	p-ClC6H4CH2	1f	8f	92	
7	C6H5	1g	8g	90	
8	CH3	1h	8h	86	
a Reagents and conditions: 1 (1.0 mmol), 2 (1.5 mmol), 5 (1.0 mmol),
and solvent (8 mL).

b Isolated
yield based on 1.

The chemical structure of all target derivatives (6–8) was fully characterized by infrared (IR)
spectroscopy, proton (1H) nuclear magnetic resonance (NMR),
carbon-13 (13C) NMR and high-resolution mass spectrometry
(HRMS). To further verify the structure of the target products, some
of the representative compounds (6g, 7f,
and 8b) were separately selected as representative compounds,
whose presence was unequivocally confirmed by X-ray diffraction analysis
as shown in Figure 2 (CCDC1879680, CCDC1879681, and CCDC1879683).

Figure 2 X-ray crystal structures
of 6g, 7f, and 8b; ellipsoids
are drawn at the 30% probability level.

On the basis of the above experimental results, we propose
the
mechanism for the formation of the target compounds 6 as outlined in Scheme 2. First, DMF-DMA 2 reacts with 1,3-dicarbonyl compounds 3 to form compounds 9. Next, the α-C of
EDAMs 1 serves as the nucleophilic site to attack the
carbonyl of compounds 9 through 1,2-addition reaction
promoted by the base to produce the intermediates 10.
This was followed by the imine-enamine tautomerization to obtain the
intermediates 10. Then, intermediates 10 undergo imine-enamine tautomerization and produce the intermediates 11. Afterward, the amino group of intermediates 11 attacks the C=C bond of the intermediates 11 via Michael addition following the loss of one molecule of NH(Me)2 to produce the intermediates 12 promoted by
the base. Finally, the intermediate 12 undergoes aromatization
and loses one molecule of H2O promoted by heat to give
the target compounds 6 (Scheme 2).

However, the proposed mechanism
for the formation of the target
compounds 7–8 is different from that
of compounds 6. Thus, in this work, we also proposed
the mechanism for the formation of the target compounds 7 (Scheme 3), as follows.
Initially, DMF-DMA 2 is reacted with cyclic 1,3-dicarbonyl
compounds 5 to form compounds 13. Next,
the α-C of EDAMs 1 serves as the nucleophilic site
to attack the C=C bond of compounds 13 through
the Michael addition reaction followed by the loss of one molecule
of NH(Me)2 promoted by the base to produce the intermediates 14. Then, the intermediates 14 produce the intermediate 15 via imine-enamine tautomerization promoted by the base.
Afterward, the intermediates 15 produce intermediates 16 through an intramolecular cyclization reaction. Eventually,
the intermediate 16 undergoes aromatization and, promoted
by heat, loses one molecule of H2O to give the target compounds 7 (Scheme 3).

Scheme 3 Proposed Mechanism for the Formation of APDs 7
Conclusions
In summary, we have
developed a concise method for the regioselective
synthesis of novel APDs via a base-promoted three-component cascade
reaction of EDAMs 1, DMF-DMA 2, and 1,3-dicarbonyl
compounds 3–5. This method has some
advantages, such as low-cost, simple operation without step by step
isolation and purification, high yields, the diversity of the target
compounds, readily accessible building blocks and potential biological
activity of the product. Moreover, we found two different mechanisms
of the reaction and compared the substrate 3 with 4–5. This is very interesting because the mechanism
of formation of the target compound 6 is based on substrate 3. This protocol provides a useful strategy to construct various
kinds of 2-aminoheterocycles including 2-aminopyridines, 2-aminopyrroles,
2-aminoquinolines, 2-aminoindoles, and others in the future.

Experimental
Section
General Methods
All compounds were fully characterized
by spectroscopic data. The NMR spectra were recorded on a Bruker DRX500
& DRX600. Chemical shifts (δ) are expressed in ppm, J values are given in Hz, and deuterated DMSO-d6 & CDCl3 were used as the solvent. IR
spectra were recorded on a FT-IR Thermo Nicolet Avatar 360 using a
KBr pellet. The reactions were monitored by thin layer chromatography
using silica gel GF254. The melting points were determined
on a XT-4A melting point apparatus and are uncorrected. HRMs were
performed on an Agilent LC/Msd TOF instrument.

Materials used
were purchased from Adamas-beta Corporation Limited. All chemicals
and solvents were used as received without further purification unless
otherwise noted. Column chromatography was performed on silica gel
(200–300 mesh). EDAMs 1 were prepared according
to the literature.41,42

General Procedure for the
Synthesis of Compounds 6–8
A 25 mL round bottom flask
was charged with 1,3-dicarbonyl compounds 3–5 (1.0 mmol), 1,4-dioxane (8 mL), and
DMF-DMA 2 (1.5 mmol). The mixture was reflux for about
0.5 h. Next, EDAMs 1 (1.0 mmol) and a small amount of
Cs2CO3 (0.05 mmol) were added to this mixture,
and the solution was stirred for about 5–10 h at reflux. Then,
the mixture was cooled to room temperature and added to 50 mL of water,
followed by extraction with an appropriate amount of ethyl acetate.
The organic phase was combined and dried over anhydrous Na2SO4 and then concentrated under reduced pressure and purified
by fast column chromatography (with the appropriate proportion of
petroleum ether and ethyl acetate). Eventually, the target compounds 6–8 were obtained with yields of 74–93%.

Ethyl
4-methyl-6-((4-methylphenethyl)amino)-5-nitronicotinate
(6a)
Yellow solid; mp 74.0 °C; IR (KBr):
3417, 2956, 1602, 1562, 1360, 1293 cm–1; 1H NMR (500 MHz, DMSO-d6): δ 1.30
(t, J = 7.0 Hz, 3H, CH3), 2.26 (s, 3H,
ArCH3), 2.51 (s, 3H, CH3), 2.79–2.81
(m, 2H, CH2), 3.60–3.64 (m, 2H, NCH2),
4.24–4.28 (m, 2H, OCH2), 7.07–7.11 (m, 4H,
ArH), 7.68 (s, 1H, CH), 8.70 (br, 1H, NH); 13C NMR (125
MHz, DMSO-d6): δ 14.5, 15.8, 21.1,
43.6, 34.7, 61.0, 114.0, 129.0, 129.3, 134.1, 135.5, 136.6, 142.7,
151.4, 153.4, 165.2. HRMS (TOF ES+) m/z: [M + H]+ calcd for C18H22N3O3, 344.1605; found, 344.1604.

Ethyl 4-methyl-5-nitro-6-(phenethylamino)nicotinate
(6b)
Yellow solid; mp 75.0 °C; IR (KBr):
3454, 2959, 1605,
1555, 1386, 1261 cm–1; 1H NMR (500 MHz,
DMSO-d6): δ 1.31 (t, J = 7.0 Hz, 3H, CH3), 2.41 (s, 3H, CH3), 2.84–2.87
(m, 2H, CH2), 3.63–3.67 (m, 2H, NCH2),
4.24–4.28 (m, 2H, OCH2), 7.18–7.22 (m, 3H,
ArH), 7.27–7.30 (m, 2H, ArH), 7.70 (s, 1H, CH) 8.70 (br, 1H,
NH); 13C NMR (125 MHz, DMSO-d6): δ 14.5, 15.8, 35.1, 42.8, 61.0, 114.1, 126.6, 128.8, 129.1,
134.2, 139.7, 142.7, 151.4, 153.4, 165.2. HRMS (TOF ES+) m/z: [M + H]+ calcd
for C17H20N3O4, 330.1448;
found, 330.1449.

Ethyl 6-((3-fluorophenethyl)amino)-4-methyl-5-nitronicotinate
(6c)
Yellow solid; mp 77.0 °C; IR (KBr):
3432, 1708, 1602, 1555, 935, 895 cm–1; 1H NMR (500 MHz, DMSO-d6): δ 1.30
(t, J = 7.0 Hz, 3H, CH3), 2.40 (s, 3H,
CH3), 2.87–2.90 (m, 2H, CH2), 3.65–3.69
(m, 2H, NCH2), 4.24–4.28 (m, 2H, OCH2), 7.01–7.05 (m, 3H, Ar), 7.30–7.33 (m, 1H, Ar), 7.68
(s, 1H, CH), 8.69 (br, 1H, NH); 13C NMR (125 MHz, DMSO-d6): δ 14.5, 15.8, 34.7, 42.4, 61.0, 113.3
(d, J = 20.0 Hz), 114.1, 115.8 (d, J = 20.0 Hz), 125.3 (d, J = 2.5 Hz), 130.6 (d, J = 7.5 Hz), 134.2, 142.7 (d, J = 15.0
Hz), 151.3, 153.3, 161.7, 163.6, 165.2. HRMS (TOF ES+) m/z: [M + H]+ calcd for C17H19FN3O4, 348.1354; found,
348.1352.

Ethyl 6-((4-chlorobenzyl)amino)-4-methyl-5-nitronicotinate
(6d)
Yellow solid; mp 89 °C; IR (KBr):
3409,
1716, 1601, 1519, 1017, 796 cm–1; 1H
NMR (500 MHz, DMSO-d6): δ 1.26 (t, J = 7.0 Hz, 3H, CH3), 2.4 (s, 3H, CH3), 4.22–4.27 (m, 2H, OCH2), 4.61–4.62 (d, J = 6.0 Hz, 2H, CH2), 7.29–7.31 (m, 2H,
ArH), 7.35–7.37 (m, 2H, ArH), 8.23 (s, 1H, CH), 863 (br, 1H,
NH); 13C NMR (125 MHz, DMSO-d6): δ 14.5, 15.8, 43.8, 61.0, 114.7, 128.7, 129.5, 131.8, 134.3,
138.8, 142.7, 151.2, 153.2, 165.1. HRMS (TOF ES+) m/z: [M + H]+ calcd for C16H17ClN3O43, 350.0902; found,
350.0899.

Ethyl 6-((4-fluorobenzyl)amino)-4-methyl-5-nitronicotinate
(6e)
Yellow solid; mp 111.0 °C; IR (KBr):
3410,
1715, 1651, 1607, 1044, 876 cm–1; 19F
NMR (470 MHz, DMSO-d6): δ −116.2; 1H NMR (500 MHz, DMSO-d6): δ
1.29 (t, J = 7.0 Hz, 3H, CH2CH3), 2.41 (s, 3H, COCH3), 4.22–4.27 (m, 2H, OCH2), 4.61–4.62 (m, 2H, CH2), 7.11–7.14
(m, 2H, ArH), 7.31–7.34 (m, 2H, ArH), 8.22 (s, 1H, CH), 8.65
(br, 1H, NH); (d, J = 240 Hz), 165.1; 13C NMR (125 MHz, DMSO-d6): δ 14.5,
15.8, 43.7, 61.0, 114.6, 115.4 (d, J = 21.3 Hz),
129.6 (d, J = 8.8 Hz), 143.3, 135.9 (d, J = 2.5 Hz), 142.7, 151.2, 153.2, 161.6 (d, J = 240.0
Hz), 165.1. HRMS (TOF ES+) m/z: [M + H]+ calcd for C16H17FN3O43, 334.1198; found, 334.1195.

1-(6-((4-Methoxyphenethyl)amino)-4-methyl-5-nitropyridin-3-yl)ethanone
(6f)
Yellow solid; mp 105.0 °C; IR (KBr):
3339, 1658, 1600, 1525, 1021, 820 cm–1; 1H NMR (500 MHz, DMSO-d6): δ 2.34
(s, 3H, COCH3), 2.50–2.54 (m, 3H, CH3), 2.78–2.80 (m, 2H, CH2), 3.60–3.64 (m,
2H, NCH2), 3.72 (s, 3H, OCH3), 6.84–6.87
(m, 2H, ArH), 7.12–7.14 (m, 2H, ArH), 7.68 (s, 1H, CH), 8.82
(br, 1H, NH); 13C NMR (125 MHz, DMSO-d6): δ 15.9, 29.6, 34.3, 43.1, 55.5, 114.3, 121.7,
130.1, 131.6, 134.9, 141.5, 150.8, 154.0, 158.2, 197.4. HRMS (TOF
ES+) m/z: [M + H]+ calcd for C17H20N3O4, 330.1448; found, 330.1446.

1-(4-Methyl-6-((4-methylphenethyl)amino)-5-nitropyridin-3-yl)ethanone
(6g)
Yellow solid; mp 115.5 °C; IR (KBr):
3402, 1671, 1598, 1551, 960, 878 cm–1; 1H NMR (500 MHz, CDCl3): δ 2.33 (S, 3H, ArCH3), 2.55 (s, 3H, CH3), 2.56 (s, 3H, COCH3), 2.89–2.91 (m, 2H, CH2), 3.77–3.81 (m,
2H, NCH2), 6.53 (s, 1H, CH), 7.10–7.12 (m, 4H, ArH),
8.69 (br, 1H, NH); 13C NMR (125 MHz, CDCl3):
δ 17.0, 21.0, 29.3, 35.0, 43.0, 123.4, 128.6, 129.4, 133.6,
135.4, 136.3, 145.4, 151.7, 153.5, 196.9. HRMS (TOF ES+) m/z: [M + H]+ calcd
for C17H20N3O3, 314.1499;
found, 314.1496.

1-(4-Methyl-5-nitro-6-(phenethylamino)pyridin-3-yl)ethanone
(6h)
Yellow solid; mp 66 °C; IR (KBr):
3373, 1674, 1665, 1593, 942, 875 cm–1; 1H NMR (500 MHz, DMSO-d6): δ 2.34
(s, 3H, CH3), 2.50–2.54 (m, 3H, COCH3), 2.85–2.88 (m, 2H, CH2), 3.64–3.68 (m,
2H, NCH2), 7.19–7.23 (m, 3H, ArH), 7.28–7.31
(m, 2H, ArH), 7.70 (s, 1H, CH), 8.82 (br, 1H, NH); 13C
NMR (125 MHz, DMSO-d6): δ 15.9,
29.6, 35.2, 42.8, 121.9, 126.6, 129.0, 129.1, 134.9, 139.8, 141.5,
150.8, 153.9, 197.4. HRMS (TOF ES+) m/z: [M + H]+ calcd for C16H18N3O3, 300.1343; found, 300.1341.

1-(6-((3-Fluorophenethyl)amino)-4-methyl-5-nitropyridin-3-yl)ethanone
(6i)
Yellow solid; mp 79.5 °C; IR (KBr):
3411, 1671, 1598, 1551, 960, 878 cm–1; 1H NMR (600 MHz, CDCl3):δ 2.55 (s, 3H, CH3), 2.57 (s, 3H, COCH3), 2.93–2.96 (m, 2H, CH2), 3.81–3.84 (m, 2H, NCH2), 6.62–6.67
(m, 1H, ArH), 6.93–6.95 (m, 2H, ArH), 6.99–7.00 (m,
1H, ArH), 7.27 (s, 1H, CH), 8.70 (br, 1H, NH); 13C NMR
(150 MHz, CDCl3): δ 17.0, 29.3, 35.2, 42.6, 113.6
(d, J = 21.0 Hz), 115.6 (d, J =
21.0 Hz), 123.6, 124.4 (d, J = 3.0 Hz), 130.2 (d, J = 9.0 Hz), 133.7, 141.1 (d, J = 7.5 Hz),
145.4, 151.6, 153.4, 160.3 (d, J = 244.5 Hz), 196.9.
HRMS (TOF ES+) m/z: [M
+ H]+ calcd for C16H17FN3O3, 318.1248; found, 318.1246.

1-(6-((2-Fluorophenethyl)amino)-4-methyl-5-nitropyridin-3-yl)ethanone
(6j)
Yellow solid; mp 89.0 °C; IR (KBr):
3410, 1673, 1604, 1525, 949, 830 cm–1; 19F NMR (470 MHz, DMSO-d6): δ −118.7; 1H NMR (500 MHz, DMSO-d6): δ
2.33 (s, 3H, COCH3), 2.51–2.53 (m, 3H, CH3), 2.90–2.92 (m, 2H, CH2), 3.67–3.68 (m,
2H, NCH2), 7.12–7.14 (m, 2H, ArH), 7.25–7.27
(m, 2H, ArH), 7.73 (s, 1H, CH), 8.80 (br, 1H, NH); 13C
NMR (125 MHz, DMSO-d6): δ 15.9,
115.5 (d, J = 22.5 Hz), 121.9, 124.8 (d, J = 3.8 Hz), 126.3 (d, J = 16.0 Hz), 128.8
(d, J = 8.9 Hz), 131.8 (d, J = 3.8
Hz), 134.9, 141.4, 150.8, 153.8, 160.3, 162.2, 197.5. HRMS (TOF ES+) m/z: [M + H]+ calcd for C16H17FN3O3, 318.1248; found, 318.1245.

1-(6-((4-Chlorobenzyl)amino)-4-methyl-5-nitropyridin-3-yl)ethanone
(6k)
Yellow solid; mp 148.0 °C; IR (KBr):
3314, 1656, 1600, 1524, 1015, 816 cm–1; 1H NMR (500 MHz, DMSO-d6): δ 2.35
(s, 3H, COCH3), 2.51 (s, 3H, CH3), 4.62–4.64
(m, 2H, CH2), 7.30–7.32 (m, 2H, ArH), 7.36–7.38 (m,
2H, ArH), 8.24 (s, 1H, CH), 875 (br, 1H, NH); 13C NMR (125
MHz, DMSO-d6): δ 15.9, 29.6, 43.7,
12.3, 128.7, 129.3, 131.8, 135.0, 138.9, 141.5, 150.6, 153.7, 197.5.
HRMS (TOF ES+) m/z: [M
+ H]+ calcd for C15H15ClN3O3, 320.0796; found, 320.0796.

1-(6-((4-Methylphenethyl)amino)-5-nitro-4-(trifluoromethyl)pyridin-3-yl)ethanone
(6l)
Yellow solid; mp 80.0 °C; IR (KBr):
3440, 1617, 1582, 1516, 943, 869 cm–1; 19F NMR (470 MHz, DMSO-d6): δ −68.1,
−61.4; 1H NMR (500 MHz, DMSO-d6): δ 2.53 (s, 3H, CH3), 2.79–2.82
(m, 2H, CH2), 3.57–3.61 (m, 2H, NCH2),
7.05–7.11 (m, 4H, ArH), 7.39 (s, 1H, CH), 8.16 (br, 1H, NH); 13C NMR (125 MHz, DMSO-d6): δ
21.6, 34.2, 43.6, 104.2, 120.6 (d, J = 272.5 Hz),
121.2 (d, J = 273.8 Hz), 124.2, 129.0, 129.4, 130.6,
132.3 (d, J = 35.0 Hz), 135.6, 136.3, 148.4 (d, J = 35.0 Hz), 150.7. HRMS (TOF ES+) m/z: [M + H]+ calcd for C17H14F6N3O3, 422.0934;
found, 538.2265.

2,2,2-Trifluoro-1-(6-((2-fluorophenethyl)amino)-5-nitro-4-(trifluoromethyl)pyridin-3-yl)ethanone
(6m)
Yellow solid; mp 82.0 °C; IR (KBr):
3455, 1624, 1581, 1532, 949, 851 cm–1; 19F NMR (470 MHz, DMSO-d6): δ −61.4,
−68.1, −119.0; 1H NMR (500 MHz, DMSO-d6): δ 2.53 (s, 3H, CH3), 2.90–2.93
(m, 2H, CH2), 3.64–3.68 (m, 2H, NCH2),
7.09–7.13 (m, 2H, ArH), 7.22–7.27 (m, 2H, ArH), 7.38
(s, 1H, CH), 8.19 (br, 1H, NH); 13C NMR (125 MHz, DMSO-d6): δ 28.1, 41.9, 104.2, 115.5 (d, J = 21.3 Hz), 119.0 (d, J = 273.8 Hz),
120.5 (d, J = 273.8 Hz), 123.8, 124.6 (d, J = 25.0 Hz), 126.0, 128.8 (d, J = 8.8
Hz), 130.6, 132.3 (d, J = 35.0 Hz), 148.4 (d, J = 35.0 Hz), 150.7, 160.3, 162.2. HRMS (TOF ES+) m/z: [M + H]+ calcd
for C16H11F7N3O3, 426.0683 found, 538.2265.

(6-((4-Chlorobenzyl)amino)-5-nitro-4-(trifluoromethyl)pyridin-3-yl)(phenyl)methanone
(6n)
Yellow solid; mp 102.0 °C; IR (KBr):
3421, 1619, 1565, 1016, 855 cm–1; 1H
NMR (500 MHz, DMSO-d6): δ 4.73–4.74
(m, 2H, NCH2), 7.37–7.41 (m, 4H, ArH), 7.42–7.49
(m, 3H, ArH), 7.51–7.57 (m, 1H, ArH), 8.05 (s, 1H, CH), 8.43
(br, 1H, NH); 13C NMR (125 MHz, DMSO-d6): δ 44.3 (d, J = 31.3 Hz), 110.3,
121.1 (d, J = 273.8 Hz), 127.8 (d, J = 23.8 Hz), 128.6 (d, J = 12.5 Hz), 129.4 (d, J = 23.4 Hz), 130.2 (d, J = 15.0 Hz), 131.5,
132.0, 133.6, 134.7, 138.6, 139.1, 145.9, 146.7 (d, J = 35.0 Hz), 150.1. HRMS (TOF ES+) m/z: [M + H]+ calcd for C20H14ClF3N3O3, 436.0670; found, 436.0673.

(5-Nitro-6-(phenethylamino)-4-phenylpyridin-3-yl)(phenyl)methanone
(6o)
Yellow solid; mp 133.0 °C; IR (KBr):
3424, 1654, 1600, 1588, 982, 959 cm–1; 1H NMR (500 MHz, DMSO-d6): δ 2.91–2.94
(m, 2H, CH2), 3.71–3.73 (m, 2H, NCH2),
7.11–7.13 (m, 2H, ArH), 7.22–7.24 (m, 4H, ArH), 7.26–7.27
(m, 2H, ArH), 7.29–7.31 (m, 2H, ArH), 7.35–7.38 (m,
2H, ArH), 7.49–7.53 (m, 1H, ArH), 7.58–7.60 (m, 2H,
ArH), 7.75–7.76 (m, 1H, CH), 8.39 (br, 1H, NH); 13C NMR (125 MHz, DMSO-d6): δ 35.2,
43.0, 123.7, 126.6, 128.3, 128.7, 128.9, 128.9, 129.1, 129.1, 129.1,
132.1, 133.58 (d, J = 25.0 Hz), 137.8, 139.8, 143.7,
150.9, 151.7, 193.8. HRMS (TOF ES+) m/z: [M + H]+ calcd for C26H22N3O3, 424.1656; found, 424.1653.

(6-((2-Fluorophenethyl)amino)-5-nitro-4-phenylpyridin-3-yl)(phenyl)methanone
(6p)
Yellow solid; mp 99.6 °C; IR (KBr):
3406, 1654, 1592, 1513, 983, 805 cm–1; 19F NMR (470 MHz, DMSO-d6): δ −118.5
Hz; 1H NMR (500 MHz, DMSO-d6): δ 2.95–2.98 (m, 2H, CH2), 3.72–3.76
(m, 2H, NCH2), 7.10–7.17 (m, 4H, ArH), 7.23–7.24
(m, 3H, ArH), 7.27–7.29 (m, 1H, ArH), 7.31–7.50 (m,
3H, ArH), 7.50–7.51 (m, 3H, ArH), 7.57–7.59 (m, 2H,
ArH), 7.78 (s, 1H, CH), 8.36 (br, 1H, NH); 13C NMR (125
MHz, DMSO-d6): δ 28.7, 41.6, 115.5
(d, J = 21.3 Hz), 123.7, 124.8, 126.4, 127.8, 128.3,
128.8, 128.8, 129.2, 129.9, 131.2, 131.8 (d, J =
5.0 Hz), 133.5 (d, J = 18.8 Hz), 137.8, 143.6, 150.9,
151.6, 160.3, 162.2, 193.8. HRMS (TOF ES+) m/z: [M + H]+ calcd for C26H21FN3O3, 442.1561; found, 442.1558.

2-((3-Methoxyphenethyl)amino)-7,7-dimethyl-3-nitro-7,8-dihydroquinolin-5(6H)-one
(7a)
Yellow solid; mp 92.0 °C; IR (KBr):
3325, 1681, 1666, 1592, 1036, 818 cm–1; 1H NMR (500 MHz, CDCl3): δ 1.00 (s, 6H, CCH3, CCH3), 2.48–2.51 (m, 2H, COCH2), 2.86–2.89
(m, 4H, CCH2, CH2), 3.71 (s, 3H, OCH3), 3.81–3.85 (m, 2H, NCH2), 6.85–6.87 (m,
2H, ArH), 7.17–7.18 (m, 2H, ArH), 8.64 (s, 1H, CH), 8.92 (br,
1H, NH); 13C NMR (125 MHz, CDCl3): δ 28.3,
32.7, 34.4, 43.4, 46.6, 51.2, 55.5, 114.4, 117.2, 127.5, 130.2, 131.4,
133.8, 153.1, 158.3, 169.6, 195.1. HRMS (TOF ES+) m/z: [M + H]+ calcd for C20H24N3O4, 370.1761; found,
370.1762.

7,7-Dimethyl-2-((4-methylphenethyl)amino)-3-nitro-7,8-dihydroquinolin-5(6H)-one
(7b)
Yellow solid; mp 107.5 °C; IR (KBr):
3392, 1678, 1517, 958, 811 cm–1; 1H NMR
(500 MHz, DMSO-d6): δ 1.02 (s, 6H,
CCH3, CCH3), 2.26 (s, 3H, CH3), 2.48–2.51
(m, 2H, COCH2), 2.86–2.90 (m, 4H, CH2, CCH2), 3.82–3.86 (m, 2H, NCH2), 7.10–7.11
(m, 1H, ArH), 7.14–7.16 (m, 2H, ArH), 8.63 (s, 1H, CH), 8.93
(br, 1H, NH); 13C NMR (125 MHz, DMSO-d6): δ 21.1, 28.2, 32.6, 34.8, 43.2, 46.5, 51.1,
117.1, 127.5, 129.0, 129.4, 133.7, 135.6, 136.4, 153.0, 169.5, 195.0.
HRMS (TOF ES+) m/z: [M
+ H]+ calcd for C20H14N3O3, 354.1812; found, 354.1810.

7,7-Dimethyl-3-nitro-2-(phenethylamino)-7,8-dihydroquinolin-5(6H)-one
(7c)
Yellow solid; mp 172.0 °C; IR (KBr):
3392, 1679, 1600, 1525, 1070, 857 cm–1; 1H NMR (500 MHz, DMSO-d6): δ 1.03
(s, 6H, CH3, CH3), 2.48–2.50 (m, 2H,
COCH2), 2.87 (s, 2H, CCH2), 2.93–2.96
(m, 2H, CH2), 3.85–3.89 (m, 2H, NCH2),
7.21–7.22 (m, 1H, ArH), 7.28–7.32 (m, 3H, ArH), 8.64
(s, 1H, CH), 8.95 (br, 1H, NH); 13C NMR (125 MHz, DMSO-d6): δ 28.3, 32.7, 35.2, 43.1, 46.5, 51.2,
117.2, 126.7, 127.5, 128.9, 129.2, 133.7, 139.5, 153.0, 169.5, 195.1.
HRMS (TOF ES+) m/z: [M
+ H]+ calcd for C19H22N3O3, 340.1656; found, 340.1655.

2-((3-Fluorophenethyl)amino)-7,7-dimethyl-3-nitro-7,8-dihydroquinolin-5(6H)-one
(7d)
Yellow solid; mp 165.0 °C; IR (KBr):
3395, 1679, 16 001, 1525, 941, 866 cm–1; 19F NMR (470 MHz, DMSO-d6): δ
−113.6; 1H NMR (500 MHz, DMSO-d6): δ 1.02 (s, 6H, CCH3, CCH3), 2.48–2.51 (m, 2H, COCH2), 2.86 (s, 2H, CCH2), 2.96–2.99 (m, 2H, CH2), 3.88–3.90
(m, 2H, NCH2), 7.01–7.03 (m, 1H, ArH), 7.09–7.13
(m, 2H, ArH), 7.32–7.34 (m, 1H, ArH), 8.64 (s, 1H, CH), 8.95
(br, 1H, NH); 13C NMR (125 MHz, DMSO-d6): δ 28.2, 32.6, 34.9, 42.6, 46.5, 51.1, 113.5
(d, J = 21.3 Hz), 115.9 (d, J =
20 Hz), 117.2, 125.4 (d, J = 1.25 Hz), 127.5, 130.6
(d, J = 8.75 Hz), 133.7, 142.6 (d, J = 7.5 Hz), 153.0, 162.7(d, J = 241.3 Hz), 169.4,
195.1. HRMS (TOF ES+) m/z: [M + H]+ calcd for C19H21FN3O3, 358.1561; found, 358.1563.

2-((2-Fluorophenethyl)amino)-7,7-dimethyl-3-nitro-7,8-dihydroquinolin-5(6H)-one
(7e)
Yellow solid; mp 187.0 °C; IR (KBr):
3385, 1680, 1601, 957, 859 cm–1; 1H NMR
(500 MHz, DMSO-d6): δ 1.01 (s, 3H,
CH3), 1.02 (s,3H, CH3), 2.47–2.51 (m,
2H, COCH2), 2.82–2.83 (s, 2H, CH2), 2.99
(s, 2H, CCH2), 3.88–3.90 (m, 2H, NCH2), 7.10–7.16 (m, 2H, ArH), 7.24–7.25 (m, 1H, ArH),
7.30–7.32 (m, 1H, ArH), 8.63 (s, 1H, CH), 9.01 (br, 1H, NH); 13C NMR (125 MHz, DMSO-d6): δ
28.3, 28.7, 32.6, 41.6, 46.4, 51.2, 115.4, 115.6, 117.2, 124.8, 126.2,
126.3, 127.5, 128.9, 131.8, 133.7, 153.1, 169.4, 195.1. HRMS (TOF
ES+) m/z: [M + H]+ calcd for C19H21FN3O3, 358.1561; found, 358.1563.

2-((4-Chlorobenzyl)amino)-7,7-dimethyl-3-nitro-7,8-dihydroquinolin-5(6H)-one
(7f)
Yellow solid; mp 162.5 °C; IR (KBr):
3385, 1682, 1592, 1574, 977, 853 cm–1; 1H NMR (500 MHz, DMSO-d6): δ 1.00
(s, 6H, CCH3, CCH3), 2.47–2.51 (m, 2H,
COCH2), 2.83 (s, 2H, CCH2), 4.81–4.82
(m, 2H, CH2), 7.36–7.383 (m, 2H, ArH), 7.43–7.44
(m, 2H, ArH), 8.66 (s, 1H, CH), 9.44 (br, 1H, NH); 13C
NMR (125 MHz, DMSO-d6): δ 28.2,
32.7, 44.2, 46.4, 51.1, 117.5, 127.8, 128.7, 128.7, 130.1, 132.0,
133.7, 155.8, 169.3, 195.1. HRMS (TOF ES+) m/z: [M + H]+ calcd for C18H19ClN3O3, 360.1109, found, 360.1109.

2-((4-Fluorobenzyl)amino)-7,7-dimethyl-3-nitro-7,8-dihydroquinolin-5(6H)-one
(7g)
Yellow solid; mp 124.0 °C; IR (KBr):
3379, 1683, 1591, 1502, 974, 852 cm–1; 19F NMR (470 MHz, DMSO-d6): δ −115.8; 1H NMR (500 MHz, DMSO-d6): δ
1.00 (s, 6H, CCH3, CCH3), 2.0 (s, 2H, COCH2), 2.85 (s, 2H, CCH2), 4.81–4.82 (m, 2H,
CH2), 7.12–7.16 (m, 2H, ArH), 7.45–7.48 (m,
2H, ArH), 8.66 (s, 1H, CH), 9.42 (br, 1H, NH); 13C NMR
(125 MHz, DMSO-d6): δ 28.2, 32.7,
44.1, 46.4, 51.1, 115.4 (d, J = 21.3 Hz), 117.5,
127.8, 130.3 (d, J = 8.8 Hz), 133.7, 135.5, 152.8,
161.7 (d, J = 241.3 Hz), 169.3, 195.1. HRMS (TOF
ES+) m/z: [M + H]+ calcd for C18H19FN3O3, 344.1405; found, 344.1404.

7,7-Dimethyl-3-nitro-2-(phenylamino)-7,8-dihydroquinolin-5(6H)-one
(7h)
Yellow solid; mp 85 °C; IR (KBr):
3438, 1735, 16 311, 1461, 1190, 840 cm–1; 1H NMR (500 MHz, DMSO-d6): δ
1.03 (s, 6H, CCH3, CCH3), 2.89 (s, 2H, COCH2), 3.35 (s, 2H, CCH2), 7.22 (s, 1H, ArH), 7.42
(s, 2H, ArH), 7.74 (s, 2H, ArH), 8.73 (s, 1H, CH), 10.32 (br, 1H,
NH); 13C NMR (125 MHz, DMSO-d6): δ 28.2, 32.8, 46.2, 51.1, 119.0, 123.6, 125.5, 128.7, 129.2,
133.8, 138.1, 150.8, 168.9, 195.2. HRMS (TOF ES+) m/z: [M + H]+ calcd for C17H17N3O3, 312.1343; found,
312.1338.

2-((4-Methoxyphenethyl)amino)-3-nitro-7,8-dihydroquinolin-5(6H)-one
(7i)
Yellow solid; mp 129.0 °C; IR (KBr):
3365, 1672, 1603, 1512, 914, 809 cm–1; 1H NMR (500 MHz, DMSO-d6): δ 2.02–2.07
(m, 2H, CH2), 2.55–2.58 (m, 2H, COCH2), 2.85–2.88 (m, 2H, ArCH2), 2.92–2.95 (m,
2H, CCH2), 3.72 (s, 2H, OCH3), 3.78–3.82
(m, 2H, NCH2), 6.85–6.87 (m, 2H, ArH), 7.17–7.19
(m, 2H, ArH), 8.63 (s, 1H, CH), 8.89 (br, 1H, NH); 13C
NMR (125 MHz, DMSO-d6): δ 21.1,
33.1, 34.3, 37.8, 43.3, 37.8, 43.3, 55.5, 114.3, 118.2, 127.5, 130.1,
131.4, 134.1, 152.6, 158.3, 170.8, 195.1. HRMS (TOF ES+) m/z: [M + H]+ calcd
for C18H20N3O4, 342.1448;
found, 342.1451.

2-((3-Methylphenethyl)amino)-3-nitro-7,8-dihydroquinolin-5(6H)-one
(7j)
Yellow solid; mp 122.0 °C; IR (KBr): 3361, 1669,
1598, 1514, 954, 844 cm–1; 1H NMR (500
MHz, DMSO-d6): δ 2.01–2.07
(m, 2H, CH2CH2CH2), 2.26 (S, 3H,
CH3), 2.50 (S, 2H, COCH2), 2.87–2.90
(m, 2H, CH2), 2.94–2.96 (m, 2H, CCH2),
3.81–3.85 (m, 2H, NCH2), 7.10–7.16 (m, 4H,
ArH), 8.65 (s, 1H, CH), 8.91 (br, 1H, NH); 13C NMR (125
MHz, CDCl3): δ 21.0, 21.2, 33.2, 35.0, 37.9, 43.1,
118.7, 127.8, 128.6, 129.4, 135.1, 135.4, 136.3, 152.7, 170.3, 195.1.
HRMS (TOF ES+) m/z: [M
+ H]+ calcd for C18H20N3O3, 326.1499; found, 326.1501.

3-Nitro-2-(phenethylamino)-7,8-dihydroquinolin-5(6H)-one
(7k)
Yellow solid; mp 130.0 °C; IR (KBr):
3374,
1671, 1598, 1572, 1134, 890 cm–1; 1H
NMR (500 MHz, DMSO-d6): δ 2.02–2.06
(m, 2H, CH2), 2.56–2.57 (m, 2H, COCH2), 2.93–2.94 (m, 4H, ArCH2, CCH2), 3.84–3.85
(m, 2H, NCH2), 7.21–7.22 (m, 1H, ArH), 7.27–7.32
(m, 4H, ArH), 8.63 (s, 1H, CH), 8.93 (br, 1H, NH); 13C
NMR (125 MHz, DMSO-d6): δ 21.1,
33.1, 35.2, 37.8, 43.1, 118.2, 126.7, 127.6, 128.9, 129.2, 134.1,
139.6, 152.6, 170.8, 195.2. HRMS (TOF ES+) m/z: [M + H]+ calcd for C17H18N3O3, 312.1343; found, 312.1342.

2-((3-Fluorophenethyl)amino)-3-nitro-7,8-dihydroquinolin-5 (6H)-one
(7l)
Yellow solid; mp 149.0 °C; IR (KBr):
3376, 1677, 1603, 1587, 1045, 907 cm–1; 19F NMR (470 MHz, DMSO-d6): δ −113.6; 1H NMR (500 MHz, DMSO-d6): δ
2.02–2.07 (m, 2H, CH2), 2.56–2.58 (t, J = 6.5 Hz, 2H, COCH2), 2.93–2.98 (m,
4H, ArCH2, CCH2), 3.85–3.89 (m, 2H, NCH2), 7.09–7.13 (m, 2H, ArH), 7.31–7.36 (m, 1H,
ArH), 8.64 (s, 1H, CH), 8.94 (br, 1H, NH); 13C NMR (125
MHz, DMSO-d6): δ 21.2, 33.1, 34.8,
37.8, 42.7, 113.5 (d, J = 20.0 Hz), 115.9 (d, J = 21.3 Hz), 118.3, 125.4 (d, J = 2.5
Hz), 127.6, 130.7 (d, J = 7.5 Hz), 134.1, 142.6 (d, J = 7.5 Hz), 152.6, 162.7 (d, J = 242.5
Hz), 170.8, 195.2. HRMS (TOF ES+) m/z: [M + H]+ calcd for C17H17FN3O3 [M + H]+, 330.1248; found, 330.1241.

2-((2-Fluorophenethyl)amino)-3-nitro-7,8-dihydroquinolin-5 (6H)-one
(7m)
Yellow solid; mp 146.0 °C; IR (KBr):
3373, 1672, 1600, 1087, 909 cm–1; 1H
NMR (500 MHz, CDCl3): δ 2.11–2.17 (m, 2H,
CH2), 2.62–2.64 (m, 2H, ArCH2), 2.96–2.98
(m, 2H, COCH2), 3.03–3.06 (m, 2H, CCH2), 3.94–3.98 (m, 2H, NCH2), 7.03–7.10 (m,
2H, ArH), 7.20–7.26 (m, 2H, ArH), 8.50 (s, 1H, CH), 8.98 (br,
1H, NH); 13C NMR (125 MHz, CDCl3): δ 21.2,
29.1, 33.2, 38.0, 41.7, 115.5 (d, J = 22.5 Hz), 118.7,
124.3, 125.4 (d, J = 15.0 Hz), 127.8, 128.6 (d, J = 7.5 Hz), 131.1 (d, J = 3.8 Hz), 135.0,
152.9, 161.4 (d, J = 243.8 Hz), 170.3, 195.2. HRMS
(TOF ES+) m/z: [M + H]+ calcd for C17H17FN3O3, 330.1248; found, 330.1248.

2-((4-Chlorobenzyl)amino)-3-nitro-7,8-dihydroquinolin-5(6H)-one
(7n)
Yellow solid; mp 109.1 °C; IR (KBr)3359,
1675, 1594, 1519, 954, 840 cm–1; 1H NMR
(500 MHz, DMSO-d6): δ 2.00–2.05
(m, 2H, CH2), 2.51–2.58 (m, 2H, COCH2), 2.88–2.91 (m, 2H, CCH2), 4.80–4.81 (m,
2H, NCH2), 7.36–7.37 (m, 2H, ArH), 7.42–7.44
(m, 2H, ArH), 8.66 (s, 1H, CH), 9.94 (br, 1H, NH); 13C
NMR (125 MHz, DMSO-d6): δ 21.1,
33.0, 37.7, 44.2, 118.6, 127.9, 128.7, 130.1, 132.0, 134.1, 138.4,
152.4, 170.6, 195.1. HRMS (TOF ES+) m/z: [M + H]+ calcd for C16H15ClN3O3, 332.0796; found, 332.0797.

2-((4-Methoxyphenethyl)amino)-3-nitro-5H-indeno[1,2-b]pyridin-5-one (8a)
Yellow solid;
mp 192.5 °C; IR (KBr): 3367, 1705, 1617, 1595, 997, 825 cm–1; 1H NMR (500 MHz, DMSO-d6): δ 2.93–2.96 (m, 2H, CH2),
3.69 (s, 3H, OCH3), 3.96–4.00 (m, 2H, NCH2), 6.86–6.88 (m, 2H, ArH), 7.24–7.25 (m, 2H, ArH),
7.67–7.70 (m, 1H, ArH), 7.75–7.81 (m, 2H, ArH), 7.91–7.92
(m, 1H, ArH), 8.47 (s, 1H, CH), 9.45 (br, 1H, NH); 13C
NMR (125 MHz, CDCl3): δ 34.7, 43.6, 55.3, 114.3,
117.5, 122.1, 123.8, 129.7, 130.3, 131.3, 132.8, 134.6, 138.3, 141.1,
156.0, 157.8, 158.6, 168.0, 170.0. HRMS (TOF ES+) m/z: [M + H]+ calcd for C21H18N3O4, 376.1292; found,
376.1292.

2-((4-Methylphenethyl)amino)-3-nitro-5H-indeno[1,2-b]pyridin-5-one (8b)
Yellow solid;
mp 197.0
°C; IR (KBr): 3356, 1708, 1616, 1585, 997, 767 cm–1; 1H NMR (600 MHz, CDCl3): δ 2.33 (s,
3H, CH3), 3.02–3.04 (m, 2H, CH2), 4.05–4.09
(m, 2H, NCH2), 7.15–7.20 (m, 3H, ArH), 7.24–7.28
(m, 1H, ArH), 7.55–7.58 (m, 1H, ArH), 7.64–7.66 (m,
1H, ArH), 7.76–7.77 (m, 1H, ArH), 7.87–7.88 (m, 1H,
ArH), 8.66 (s, 1H, CH), 9.08 (br, 1H, NH); 13C NMR (150
MHz, CDCl3): δ 21.0, 35.1, 43.5, 117.5, 122.1, 123.8,
126.9, 128.6, 129.5, 131.2, 132.8, 134.6, 135.2, 136.5, 138.3, 141.1,
155.9, 170.0, 188.7. HRMS (TOF ES+) m/z: [M + H]+ calcd for C21H18N3O3, 360.1343; found, 360.1343.

3-Nitro-2-(phenethylamino)-5H-indeno[1,2-b]pyridin-5-one
(8c)
Yellow solid; mp 168.0 °C; IR (KBr):
3360, 1711, 1622, 1596, 1045, 803 cm–1; 1H NMR (500 MHz, DMSO-d6): δ 3.00–3.02
(m, 2H, CH2), 3.96–4.00 (m, 2H, NCH2),
7.21–7.24 (m, 1H, ArH), 7.33–7.34 (m, 4H, ArH), 7.64–7.67
(m, 1H, ArH), 7.71–7.72 (m, 1H, ArH), 7.74–7.78 (m,
1H, ArH), 7.85–7.86 (m, 1H, ArH), 8.40 (s, 1H, CH), 8.51 (s,
1H, CH), 9.44 (br, 1H, NH); 13C NMR (125 MHz, DMSO-d6): δ 35.4, 43.6, 116.7, 122.3, 123.8,
126.8, 126.8, 129.0, 129.2, 131.0, 133.6, 135.6, 138.0, 139.4, 140.8,
155.6, 169.5, 188.3. HRMS (TOF ES+) m/z: [M + H]+ calcd for C20H16N3O3, 346.1186; found, 346.1186.

2-((3-Fluorophenethyl)amino)-3-nitro-5H-indeno[1,2-b]pyridin-5-one (8d)
Yellow solid;
mp 183.5
°C; IR (KBr): 3337, 1703, 1616, 1583, 997, 936 cm–1; 19F NMR (470 MHz, DMSO-d6): δ −113.3; 1H NMR (500 MHz, DMSO-d6): δ 3.06–3.09 (m, 2H, CH2), 4.06–4.10 (m, 2H, NCH2), 6.93–6.96
(m, 1H, ArH), 7.08–7.13 (m, 2H, ArH), 7.30–7.34 (m,
1H, ArH), 7.61–7.64 (m, 1H, ArH), 7.71–7.74 (m, 2H,
ArH), 8.04 (s, 1H, ArH), 8.51 (s, 1H, CH), 9.37 (br, 1H, NH); 13C NMR (125 MHz, DMSO-d6): δ
35.4, 43.0, 113.8 (d, J = 21.3 Hz), 115.6 (d, J = 20.0 Hz), 117.6, 122.1, 123.8, 124.4, 127.0, 130.3 (d, J = 8.8 Hz), 131.2, 132.9, 134.7, 138.2, 140.9 (d, J = 23.8 Hz), 115.9, 162.1, 164.1, 170.0, 188.6. HRMS (TOF
ES+) m/z: [M + H]+ calcd for C20H15FN3O3, 364.1092; found, 364.1094.

2-((2-Fluorophenethyl)amino)-3-nitro-5H-indeno[1,2-b]pyridin-5-one (8e)
Yellow solid;
mp 195.0
°C; IR (KBr): 3338, 1704, 1617, 1586, 956, 904 cm–1; 1H NMR (500 MHz, DMSO-d6): δ 3.05–3.08 (m, 2H, CH2), 4.00–4.04
(m, 2H, NCH2), 7.11–7.14 (m, 2H, ArH), 7.15–7.25
(m, 1H, ArH), 7.35–7.38 (m, 1H, ArH), 7.65–7.66 (m,
1H, ArH), 7.68–7.69 (m, 1H, ArH), 7.78–7.80 (m, 1H,
ArH), 7.81–7.87 (m, 1H, ArH), 8.44 (s, 1H, CH), 9.53 (br, 1H,
NH); 13C NMR (150 MHz, CDCl3): δ 29.4,
42.0, 115.5, 115.6, 117.6, 122.1, 123.8, 124.4, 125.3 (d, J = 16.5 Hz), 126.9, 128.7 (d, J = 7.5
Hz), 131.2 (d, J = 6.0 Hz), 132.8, 134.6, 138.2,
141.1, 156.0, 162.3, 169.9, 188.7. HRMS (TOF ES+) m/z: [M + H]+ calcd for C20H15FN3O3, 364.1092; found,
364.1094.

2-((4-Chlorobenzyl)amino)-3-nitro-5H-indeno[1,
2-b]pyridin-5-one (8f)
Yellow
solid; mp 228.0
°C; IR (KBr): 3368, 1735, 1654, 1618, 942, 836 cm–1; 1H NMR (500 MHz, DMSO-d6): δ 4.94–4.96 (m, 2H, CH2), 7.38–7.40
(m, 2H, ArH), 7.54–7.55 (m, 2H, ArH), 7.66–7.68 (m,
1H, ArH), 7.73–7.78 (m, 2H, ArH), 7.86–7.88 (m, 1H,
ArH), 8.47 (s, 1H, CH), 8.94 (br, 1H, NH); 13C NMR (125
MHz, CDCl3): δ 45.1, 118.1, 122.1, 123.9, 127.2,
129.1, 129.2, 131.3, 132.9, 133.8, 134.8, 135.9, 138.2, 141.0, 155.7,
170.0, 188.5. HRMS (TOF ES+) m/z: [M + H]+ calcd for C19H13ClN3O3, 366.0640; found, 5366.0641.

3-Nitro-2-(phenylamino)-5H-indeno[1,2-b]pyridin-5-one
(8g)
Yellow solid; mp 176.6 °C; IR (KBr):
3378, 1730, 1604, 1530, 1285.36, 1130.35 cm–1; 1H NMR (600 MHz, CDCl3): δ 7.26–7.29
(m, 1H, ArH), 7.45–7.48 (m, 2H, ArH), 7.55–7.58 (m,
1H, ArH), 7.62–7.64 (m, 1H, ArH), 7.76–7.81 (m, 1H,
ArH), 8.74 (s, 1H, CH), 10.89 (br, 1H, NH); 13C NMR (150
MHz, CDCl3): δ 119.2, 122.4, 122.9, 123.9, 125.8,
127.3, 129.1, 131.4, 133.0, 134.8, 137.1, 138.0, 140.9, 153.5, 169.8,
188.4. HRMS (TOF ES+) m/z: [M + H]+ calcd for C18H12N3O3, 318.0873; found, 318.0873.

2-(Methylamino)-3-nitro-5H-indeno[1,2-b]pyridin-5-one
(8h)
Yellow solid; mp 121.8 °C; IR (KBr):
3378, 1730, 1604, 1530, 1285, 1130 cm–1; 1H NMR (600 MHz, DMSO): δ 3.25–3.28 (d, 3H, CH3), 7.66–7.68 (m, 1H, ArH), 7.73–7.77 (m, 2H, ArH),
7.87–7.88 (m, 1H, ArH), 8.44 (s, 1H, CH), 9.41 (br, 1H, NH); 13C NMR (150 MHz, DMSO): δ 29.5, 116.4, 122.4, 123.8,
127.2, 130.9, 133.6, 135.6, 138.1, 140.9, 156.1, 169.6, 188.5. HRMS
(TOF ES+) m/z: calcd
for C13H10N3O3, 256.0717;
found, 256.0717.

Supporting Information Available
The Supporting
Information is
available free of charge on the ACS Publications website at DOI: 10.1021/acsomega.8b03284.Spectroscopic
and analytical data as well as the original
copy of 1H and 13C NMR spectra of all new compounds
(PDF)

X-ray
crystallographic data (CIF file) of compound 6g (CCDC
1879680), 7f (CCDC 1879681) and 8b (CCDC
1879683) (CIF)

Crystallographic data (CIF)

Crystallographic data (CIF)



Supplementary Material
ao8b03284_si_001.pdf

 ao8b03284_si_002.cif

 ao8b03284_si_003.cif

 ao8b03284_si_004.cif

 The authors declare no
competing financial interest.

Acknowledgments
This work was supported by the Program for Changjiang
Scholars and Innovative Research Team in University (IRT17R94), the
National Natural Science Foundation of China (nos. 21662042, 81760621,
21362042, U1202221), the Natural Science Foundation of Yunnan Province
(2017FA003), the High-Level Talents Introduction Plan of Yunnan Province,
Donglu Schloars of Yunnan University, Excellent Young Talents of Yunnan
University (XT412003). We also thank Dr. Rong Huang of Advanced Analysis
and Measurement Center of Yunnan University for helpful testing the
NMR.
==== Refs
References
Bold G. ; Fässler A. ; Capraro H.-G. ; Cozens R. ; Klimkait T. ; Lazdins J. ; Mestan J. ; Poncioni B. ; Rösel J. ; Stover D. ; Tintelnot-Blomley M. ; Acemoglu F. ; Beck W. ; Boss E. ; Eschbach M. ; Hürlimann T. ; Masso E. ; Roussel S. ; Ucci-Stoll K. ; Wyss D. ; Lang M. 
New Aza-Dipeptide Analogues as Potent
and Orally Absorbed HIV-1 Protease Inhibitors: Candidates for Clinical
Development . J. Med. Chem. 
1998 , 41 , 3387 –3401 . 10.1021/jm970873c .9719591 
Cui J. J. ; Tran-Dubé M. ; Shen H. ; Nambu M. ; Kung P.-P. ; Pairish M. ; Jia L. ; Meng J. ; Funk L. ; Botrous I. ; McTigue M. ; Grodsky N. ; Ryan K. ; Padrique E. ; Alton G. ; Timofeevski S. ; Yamazaki S. ; Li Q. ; Zou H. ; Christensen J. ; Mroczkowski B. ; Bender S. ; Kania R. S. ; Edwards M. P. 
Structure
Based Drug Design of Crizotinib (PF-02341066), a Potent and Selective
Dual Inhibitor of Mesenchymal–Epithelial Transition Factor
(c-MET) Kinase and Anaplastic Lymphoma Kinase (ALK) . J. Med. Chem. 
2011 , 54 , 6342 –6363 . 10.1021/jm2007613 .21812414 
Basit S. ; Ashraf Z. ; Lee K. ; Latif M. 
First macrocyclic 3rd-generation
ALK inhibitor for treatment of ALK/ROS1 cancer: Clinical and designing
strategy update of lorlatinib . Eur. J. Org.
Chem. 
2017 , 348 –356 . 10.1016/j.ejmech.2017.04.032 .
Schoepfer J. ; Jahnke W. ; Berellini G. ; Buonamici S. ; Cotesta S. ; Cowan-Jacob S. W. ; Dodd S. ; Drueckes P. ; Fabbro D. ; Gabriel T. ; Groell J.-M. ; Grotzfeld R. M. ; Hassan A. Q. ; Henry C. ; Iyer V. ; Jones D. ; Lombardo F. ; Loo A. ; Manley P. W. ; Pellé X. ; Rummel G. ; Salem B. ; Warmuth M. ; Wylie A. A. ; Zoller T. ; Marzinzik A. L. ; Furet P. 
Discovery of Asciminib
(ABL001), an Allosteric Inhibitor of the Tyrosine Kinase Activity
of BCR-ABL1 . J. Med. Chem. 
2018 , 61 , 8120 –8135 . 10.1021/acs.jmedchem.8b01040 .30137981 
Padget K. ; Stewart A. ; Charlton P. ; Tilby M. J. ; Austin C. A. 
An investigation
into the formation of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide
(DACA) and 6-[2-(dimethyl-amino)ethylamino]-3-hydroxy-7H-indeno[2,1-c]quinolin-7-one dihydrochloride (TAS-103)
stabilised DNA topoisomerase I and II cleavable complexes in human
leukaemia cells . Biochem. Pharmacol. 
2000 , 60 , 817 –821 . 10.1016/s0006-2952(00)00402-0 .10930536 
Aoyagi Y. ; Kobunai T. ; Utsugi T. ; Oh-hara T. ; Yamada Y. 
In vitro Antitumor
Activity of TAS-103, a Novel Quinoline Derivative That Targets Topoisomerases
I and II . Jpn. J. Cancer Res. 
2005 , 90 , 578 –587 . 10.1111/j.1349-7006.1999.tb00786.x .
Nishiguchi G. A. ; Rico A. ; Tanner H. ; Aversa R. J. ; Taft B. R. ; Subramanian S. ; Setti L. ; Burger M. T. ; Wan L. ; Tamez V. ; Smith A. ; Lou Y. ; Barsanti P. A. ; Appleton B. A. ; Mamo M. ; Tandeske L. ; Dix I. ; Tellew J. E. ; Huang S. ; Griner L. A. M. ; Cooke V. G. ; Van Abbema A. ; Merritt H. ; Ma S. ; Gampa K. ; Feng F. ; Yuan J. ; Wang Y. ; Haling J. R. ; Vaziri S. ; Hekmat-Nejad M. ; Jansen J. M. ; Polyakov V. ; Zang R. ; Sethuraman V. ; Amiri P. ; Singh M. ; Lees E. ; Shao W. ; Stuart D. D. ; Dillon M. P. ; Ramurthy S. 
Design and
Discovery of N-(2-Methyl-5′-morpholino-6′-
((tetrahydro-2H-pyran-4-yl)oxy)-[3,3′-bipyridin]-5-yl)-3-(trifluoromethyl)benzamide
(RAF709): A Potent, Selective, and Efficacious RAF Inhibitor Targeting
RAS Mutant Cancers . J. Med. Chem. 
2017 , 60 , 4869 –4881 . 10.1021/acs.jmedchem.6b01862 .28557458 
Wei M. ; Peng X. ; Xing L. ; Dai Y. ; Dai Y. ; Huang R. ; Geng M. ; Zhang A. ; Ai J. ; Song Z. 
Design, synthesis and biological evaluation of a series
of novel
2-benzamide-4-(6-oxy-N-methyl-1-naphthamide)-pyridine
derivatives as potent fibroblast growth factor receptor (FGFR) inhibitors . Eur. J. Med. Chem. 
2018 , 154 , 9 –28 . 10.1016/j.ejmech.2018.05.005 .29775937 
Li J. ; Wu N. ; Tian Y. ; Zhang J. ; Wu S. 
Aminopyridyl/Pyrazinyl
Spiro[indoline-3,4′-piperidine]-2-ones As Highly Selective
and Efficacious c-Met/ALK Inhibitors . ACS Med. Chem. Lett. 
2013 , 4 , 806 –810 . 10.1021/ml400203d .24900750 
Girgis A. S. ; Tala S. R. ; Oliferenko P. V. ; Oliferenko A. A. ; Katritzky A. R. 
Computer-assisted rational design,
synthesis, and bioassay
of non-steroidal anti-inflammatory agents . Eur.
J. Med. Chem. 
2012 , 50 , 1 –8 . 10.1016/j.ejmech.2011.11.034 .22365409 
Liu N. ; Tu J. ; Dong G. ; Wang Y. ; Sheng C. 
Emerging New Targets
for the Treatment of Resistant Fungal Infections . J. Med. Chem. 
2018 , 61 , 5484 –5511 . 10.1021/acs.jmedchem.7b01413 .29294275 
Tardioli S. ; Gooijer C. ; van der
Zwan G. 
Anomalous Photophysics of H1 Antihistamines
in Aqueous Solution . J Phys Chem B 
2009 , 113 , 6949 –57 . 10.1021/jp9005907 .19388641 
Hikawa H. ; Imamura H. ; Kikkawa S. ; Azumaya I. 
A borrowing hydrogen
methodology: palladiumcatalyzed dehydrative N-benzylation
of 2-aminopyridines in water . Green Chem. 
2018 , 20 , 3044 –3049 . 10.1039/c8gc01028e .
Iwamura R. ; Tanaka M. ; Okanari E. ; Kirihara T. ; Odani-Kawabata N. ; Shams N. ; Yoneda K. 
Identification of a Selective, Non-Prostanoid
EP2 Receptor Agonist for the Treatment of Glaucoma: Omidenepag and
its Prodrug Omidenepag Isopropyl . J. Med. Chem. 
2018 , 61 , 6869 –6891 . 10.1021/acs.jmedchem.8b00808 .29995405 
May B. C. H. ; Zorn J. A. ; Witkop J. ; Sherrill J. ; Wallace A. C. ; Legname G. ; Prusiner S. B. ; Cohen F. E. 
Structure-Activity
Relationship Study of Prion Inhibition by 2-Aminopyridine-3,5-dicarbonitrile-Based
Compounds: Parallel Synthesis, Bioactivity, and in Vitro Pharmacokinetics . J. Med. Chem. 
2007 , 50 , 65 –73 . 10.1021/jm061045z .17201410 
Mohedas A. H. ; Wang Y. ; Sanvitale C. E. ; Canning P. ; Choi S. ; Xing X. ; Bullock A. N. ; Bullock A. N. ; Cuny G. D. ; Yu P. B. 
Structure-Activity
Relationship of 3,5-Diary l-2-aminopyridine ALK2
Inhibitors Reveals Unaltered Binding Affinity for Fibrodysplasia Ossificans
Progressiva Causing Mutants . J. Med. Chem. 
2014 , 57 , 7900 –7915 . 10.1021/jm501177w .25101911 
Kang S. ; Li H. ; Tang W. ; Martásek P. ; Roman L. J. ; Poulos T. L. ; Silverman R. B. 
2-Aminopyridines with a Truncated Side Chain To Improve
Human Neuronal Nitric Oxide Synthase Inhibitory Potency and Selectivity . J. Med. Chem. 
2015 , 58 , 5548 –5560 . 10.1021/acs.jmedchem.5b00573 .26120733 
Wang H.-Y. ; Qin Y. ; Li H. ; Roman L. J. ; Martásek P. ; Poulos T. L. ; Silverman R. B. 
Potent and Selective Human Neuronal
Nitric Oxide Synthase Inhibition by Optimization of the 2-Aminopyridine-Based
Scaffold with a Pyridine Linker . J. Med. Chem. 
2016 , 59 , 4913 –4925 . 10.1021/acs.jmedchem.6b00273 .27050842 
Averill K. M. ; Demarest K. T. ; Tang Y. ; Heintzelman G. R. ; Dodd J. H. ; Jackson P. F.  ; Arylindenopyridines
And Related Therapeutic And Prophylactic Methods .
U.S. Patent 2006/154,949 A1 , 2006 .
Siu M. ; Ghosh A. S. ; Lewcock J. W. 
Dual Leucine Zipper Kinase Inhibitors
for the Treatment of Neurodegeneration . J. Med.
Chem. 
2018 , 61 , 8078 –8087 . 10.1021/acs.jmedchem.8b00370 .29863360 
Girgis A. S. ; Mishriky N. ; Farag A. M. ; El-Eraky W. I. ; Farag H. 
Synthesis
of new 3-pyridinecarboxylates of potential vasodilation properties . Eur. J. Med. Chem. 
2008 , 43 , 1818 –1827 . 10.1016/j.ejmech.2007.11.025 .18241958 
Girgis A. S. ; Tala S. R. ; Oliferenko P. V. ; Oliferenko A. A. ; Katritzky A. R. 
Computer-assisted rational design, synthesis, and bioassay
of non-steroidal anti-inflammatory agents . Eur.
J. Med. Chem. 
2012 , 50 , 1 –8 . 10.1016/j.ejmech.2011.11.034 .22365409 
Kumar D. ; Vemula S. R. ; Cook G. R. 
Merging
C–H Bond Functionalization
with Amide Alcoholysis: En Route to 2-Aminopyridines . ACS Catal. 
2016 , 6 , 3531 –3536 . 10.1021/acscatal.6b00728 .
Cheng G. ; Weng Y. ; Yang X. ; Cui X. 
Base-Promoted N-Pyridylation of Heteroarenes Using N-Propargyl
Enaminones as Equivalents of Pyridine Scaffolds . Org. Lett. 
2015 , 17 , 3790 –3793 . 10.1021/acs.orglett.5b01733 .26200227 
Weng Y. ; Kuai C. ; Lv W. ; Cheng G. 
Synthesis of 2-Aminopyridines via a Base-Promoted
Cascade Reaction of N-Propargylic β-Enaminones with Formamides . J. Org. Chem. 
2018 , 83 , 5002 –5008 . 10.1021/acs.joc.8b00128 .29651837 
Ye F. ; Haddad M. ; Ratovelomanana-Vidal V. ; Michelet V. 
Ruthenium-Catalyzed
[2+2 +2] Cycloaddition Reaction Forming 2-Aminopyridine Derivatives
from α,ω-Diynes and Cyanamides . Org. Lett. 
2017 , 19 , 1104 –1107 . 10.1021/acs.orglett.7b00130 .28225282 
a Wu Q. ; Zhang Y. ; Cui S. 
Divergent
Syntheses of 2-Aminonicotinonitriles and Pyrazolines by Copper-Catalyzed
Cyclization of Oxime Ester . Org. Lett. 
2014 , 16 , 1350 –1353 . 10.1021/ol500094w .24571784  b Xie L.-Y. ; Qu J. ; Peng S. ; Liu K.-J. ; Wang Z. ; Ding M.-H. ; Wang Y. ; Cao Z. ; He W.-M. 
Selectfluor-mediated regioselective nucleophilic functionalization
of N-heterocycles under metal- and base-free conditions . Green Chem. 
2018 , 20 , 760 –764 . 10.1039/c7gc03106h . c Xie L.-Y. ; Peng S. ; Lu L.-H. ; Hu J. ; Bao W.-H. ; Zeng F. ; Tang Z. ; Xu X. ; He W.-M. 
Brønsted Acidic Ionic Liquid-Promoted Amidation of Quinoline
N-Oxides with Nitriles . ACS Sustainable Chem.
Eng. 
2018 , 6 , 7989 –7994 . 10.1021/acssuschemeng.8b01358 . d Lu L.-H. ; Zhou S.-J. ; Sun M. ; Chen J.-L. ; Xia W. ; Yu X. ; Xu X. ; He W.-M. 
Metal- and Solvent-Free
Ultrasonic Multicomponent Synthesis of (Z)-β-Iodo Vinylthiocyanates . ACS
Sustainable Chem. Eng. 
2018 , 7 , 1574 –1579 . 10.1021/acssuschemeng.8b05344 . e Xie L.-Y. ; Peng S. ; Jiang L.-L. ; Peng X. ; Xia W. ; Yu X. ; Wang X.-X. ; Cao Z. ; He W.-M. 
AgBF4-catalyzed deoxygenative C2-amination of quinoline N-oxides with isothiocyanates . Org.
Chem. Front. 
2019 , 6 , 167 –171 . 10.1039/c8qo01128a .
Tseng C.-H. ; Tzeng C.-C. ; Yang C.-L. ; Lu P.-J. ; Chen H.-L. ; Li H.-Y. ; Chuang Y.-C. ; Yang C.-N. ; Chen Y.-L. 
Synthesis
and Antiproliferative Evaluation of Certain Indeno[1,2-c]quinoline Derivatives. Part 2 . J. Med. Chem. 
2010 , 53 , 6164 –6179 . 10.1021/jm1005447 .20662543 
Hranjec M. ; Pavlović G. ; Marjanović M. ; Kralj M. ; Karminski-Zamola G. 
Benzimidazole
derivatives related to 2,3-acrylonitriles, benzimidazo[1,2-a]quinolines and fluorenes: Synthesis, antitumor evaluation
in vitro and crystal structure determination . Eur. J. Med. Chem. 
2010 , 45 , 2405 –2417 . 10.1016/j.ejmech.2010.02.022 .20207049 
Yu F. ; Yan S. ; Hu L. ; Wang Y. ; Lin J. 
Cascade Reaction of
Isatins with Heterocyclic Ketene Aminals: Synthesis of Imidazopyrroloquinoline
Derivatives . Org. Lett. 
2011 , 13 , 4782 –4785 . 10.1021/ol201783d .21848302 
Xu H. ; Zhou B. ; Zhou P. ; Zhou J. ; Shen Y. ; Yu F.-C. ; Lu L.-L. 
Insights into the unexpected chemoselectivity
in Brøsted acid catalyzed cyclization of isatins with enaminones:
convenient synthesis of pyrrolo[3,4-c]quinolin-1-ones
and spirooxindoles . Chem. Commun. 
2016 , 52 , 8002 –8005 . 10.1039/c6cc02659a .
Xu H. ; Zhou P. ; Zhou B. ; Zhou J. ; Shen Y. ; Lu L.-L. ; Yu F.-C. 
Convenient one-step synthesis of
pyrrolo[3,4-c] quinolin-1-ones via TMSCl-catalyzed cascade reactions of isatins and β-enamino ketones . RSC Adv. 
2016 , 6 , 73760 –73768 . 10.1039/c6ra15492a .
Wang K.-M. ; Yan S.-J. ; Lin J. 
Heterocyclic Ketene Aminals: Scaffolds
for Heterocycle Molecular Diversity . Eur. J.
Org. Chem. 
2013 , 1129 –1145 . 10.1002/ejoc.201300929 .
Chen N. ; Meng X. ; Zhu F. ; Cheng J. ; Shao X. ; Li Z. 
Tetrahydroindeno-[1′,2′:4,5]pyrrolo[1,2-a]imidazol-5(1H)-ones as Novel Neonicotinoid
Insecticides:
Reaction Selectivity and Substituent Effects on the Activity Level . J. Agric. Food Chem. 
2015 , 63 , 1360 –1369 . 10.1021/jf505281p .25611859 
Chen L. ; Huang R. ; Du X.-X. ; Yan S.-J. ; Lin J. 
One-Pot Synthesis
of Highly Functionalized Bicyclic Imidazopyridinium Derivatives in
Ethanol . ACS Sustainable Chem. Eng. 
2017 , 5 , 1899 –1905 . 10.1021/acssuschemeng.6b02622 .
Li M. ; Shao P. ; Wang S.-W. ; Kong W. ; Wen L.-R. 
Four-Component
Cascade Heteroannulation of Heterocyclic Ketene Aminals: Synthesis
of Functionalized Tetrahydroimidazo[1,2-a]pyridine
Derivatives . J. Org. Chem. 
2012 , 77 , 8956 –8967 . 10.1021/jo3013836 .22970749 
Ma Y.-L. ; Wang K.-M. ; Huang R. ; Lin J. ; Yan S.-J. 
An environmentally
benign double Michael addition reaction of heterocyclic ketene aminals
with quinone monoketals for diastereoselective synthesis of highly
functionalized morphan derivatives in water . Green Chem. 
2017 , 19 , 3574 –3584 . 10.1039/c7gc01435j .
Wang B.-Q. ; Zhang C.-H. ; Tian X.-X. ; Lin J. ; Yan S.-J. 
Cascade
Reaction of Isatins with 1,1-Enediamines: Synthesis of Multisubstituted
Quinoline-4-carboxamides . Org. Lett. 
2018 , 20 , 660 –663 . 10.1021/acs.orglett.7b03803 .29323495 
Zhang C.-H. ; Huang R. ; Hu X.-M. ; Lin J. ; Yan S.-J. 
Three-Component
Site-Selective Synthesis of Highly Substituted 5H-Chromeno-[4,3-b]pyridines . J. Org. Chem. 
2018 , 83 , 4981 –4989 . 10.1021/acs.joc.8b00099 .29648823 
Chen X.-B. ; Liu Z.-C. ; Yang L.-F. ; Yan S.-J. ; Lin J. 
A Three-Component
Catalyst-Free Approach to Regioselective Synthesis of Dual Highly
Functionalized Fused Pyrrole Derivatives in Water–Ethanol Media:
Thermodynamics versus Kinetics . ACS Sustainable
Chem. Eng. 
2014 , 2 , 1155 –1163 . 10.1021/sc500170d .
Mertens H. ; Troschuetz R. ; Roth H. J. 
Synthese primärer Nitroketenaminale . Arch. Pharm. 
1986 , 319 , 161 –167 . 10.1002/ardp.19863190213 .
Hu X.-M. ; Luo D.-Y. ; Zi Q.-X. ; Lin J. ; Yan S.-J. 
Diastereoselective
Synthesis of Morphan Derivatives by Michael and Hetero-Michael Addition
of 1,1-Enediamines to Quinone Monoketals . ACS
Omega 
1986 , 3 , 8 –21 . 10.1021/acsomega.7b01493 .

